Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine-based Chemotherapy plus ICIs in Advanced Biliary Malignancies
NCT05487443Phase 3Unknown
- Sponsor
- Hangzhou First People's Hospital
- Start
- Aug 2022
- Primary completion
- Sep 2023
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial in biliary tract cancer (BTC), sponsored by Hangzhou First People's Hospital. Primary endpoint: Progression Free Survival at 1 month. Status: unknown.
02
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05487443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05487443.